Is Infuse Better for Spinal Fusion? New Studies Say No

Written by Ellie Rizzo | June 18, 2013 | Print  |
The newest issue of the Annals of Internal Medicine contains two studies evaluating the safety and effectiveness of Medtronic's recombinant human bone morphogenic protein, Infuse, in spinal fusion surgery.

The studies meta-analyzed data from spinal fusion surgeries that used iiliac crest bone grafts as well as data from Medtronic on patients treated with Infuse.

While the Medtronic product appeared similarly effective to iliac crest bone grafts, both pain and cancer were more commonly reported after the use of Infuse.

Both studies concluded that while Infuse is comparably effective to an iliac crest bone graft, it is correlated with adverse outcomes such as little pain reduction and cancer at higher rates post-surgery.

The studies were funded by Yale University and Medtronic. For the North American Spine Society response to the studies, click here.

More Articles on Spine
Medtronic Files to Dismiss Whistleblower Lawsuit
New Technologies to Make Spine Surgery Safer: Q&A With Dr. William Sonstein
Medtronic Receives CE Mark, Initiates European Launch of Spinal Deformity Instrument

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers